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ABSTRACT 
DREADD Targeting Projections from the Nucleus Accumbens to the Ventral Pallidum with 
Nicotine Self-Administration 
by 
Amanda L. Smith 
 
Projections from the Nucleus Accumbens (NAc) to the Ventral Pallidum (VP) play a critical role 
in motivation and reward. Rewards and reward-associated cues are thought to alter this pathway 
by suppressing GABA release to the VP, however, the role of the NAc to VP pathway has never 
been investigated with regard to nicotine self-administration. We hypothesized that increasing 
GABAergic signaling from the NAc to the VP would decrease the reinforcing effects of nicotine. 
To increase GABA release, CRE dependent DREADD was expressed in the NAc of male rats. 
Administration of low dose clozapine activated the DREADD receptor and showed a reduction 
in responding for nicotine suggesting that activation of the NAc to VP pathway reduced 
reinforcement. However, a nonspecific effect was observed leading to future investigation of 
locomotor activity. Immunohistochemistry and microdialysis were used to confirm DREADD 
expression in the NAc and increased extracellular GABA in the VP.  
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CHAPTER 1 
LITERATURE REVIEW  
Project Overview  
 Substance dependence is widely considered to be a ‘brain disease’ – or, more specifically 
a disorder of maladaptive neuroplasticity (Nestler 2014). External stimuli, cognition, behavior, 
and emotion can remap the brain to alter its responses to future circumstances (Fuchs and Flügge 
2014). Drugs of abuse can directly alter neuroplasticity in circuits that mediate motivation and 
approach behaviors, distorting the reward and reinforcement derived from the addictive drug and 
its associated stimuli (Lüscher and Malenka 2011). These synaptic changes in brain circuits can 
lead to craving, unsuccessful quit attempts, and taking the drug in increasing amounts. 
Dependence (used interchangeably with ‘addiction’) is traditionally defined as ‘loss of control’ 
over drug taking - most addicts will continue to use a substance despite persistent problems 
related to taking the drug (American Psychiatric Association 2014). A common example is a 
chronic smoker continuing to smoke tobacco cigarettes after the diagnoses of a chronic 
respiratory disease, like emphysema. Even with negative consequences, motivation to seek and 
consume the drug still persists. Drugs of abuse are portrayed to ‘hijack’ the brains reward system 
promoting changes that lead to impair judgement, memory, and decision making (Pfaus and 
Blaustein 2015; National Institute of Drug Abuse 2018). A large amount of funding and research 
been invested into understanding why humans continue to desire a drug. Clinical trials use 
imaging, like fMRI or functional magnetic resonance imaging, to show what areas of the brain 
are activated during cravings, reward, or withdrawal. However, it is not plausible to use a human 
model when converging the neurobiology behind the behavior. The best alternative option is 
using an animal model which allows for more diverse methods when investigating dependence.  
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Animal Model 
 Animal models of substance dependence have provided more perspective about the 
complex neurobiology of this disorder. Conditioned place preference, intracranial self-
stimulation, and drug self-administration are a few of the developed models that have allowed 
researchers to observe behavior and further understand the function of reward and motivation in 
non-human animals (Feltenstein and See 2008). Rodents Rats have the ability to perform 
multifaceted cognitive tasks which allow for highly translational data and invasive manipulations 
(Iannaccone and Jacob 2009). Not only has rodent behavioral testing shown relevance to clinical 
studies but has also provided validity of the similarities in neurochemical and neuroanatomy 
involved in drug-associated behaviors between rodents and humans. Rodents will not only 
voluntarily self-administer the same abusive drugs but will do so in comparable ways including 
intravenous and orally self-administration (Spanagel 2017). The animal model is an excellent 
way to further understand the changes in the reward pathway associated to drug use specifically 
the more common consumed drug, nicotine.  
Nicotine 
 Nicotine is a readily available psychostimulant found in tobacco cigarettes, smokeless 
tobacco, and vaping products. In the United States, smoking tobacco cigarettes is one of the 
leading causes of smoking-related premature deaths including cancer, cardiovascular disease, 
and pulmonary diseases. An estimated 45 million Americans smoke with only 3% successfully 
quitting (Benowitz 2010). Heath risks of smoking or the use of smokeless tobacco are well 
known and yet many still persist. Evidence has shown that nicotine alters the brains natural 
reward system leading to dependence (Tomkins and Sellers 2001). The reward system is referred 
to as the mesolimbic dopaminergic system and is a common target among all drugs of abuse 
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(Lüscher and Malenka 2011). Nicotine controls the mesolimbic system by binding to 42 
nicotinic acetylcholine receptors expressed on dopaminergic neurons increasing pleasure and 
mood (Benowitz 2010). The psychostimulant effects of nicotine may not be comparable to 
cocaine or other drugs of abuse. It does, however, activate the same dopaminergic pathways 
making nicotine a reliable drug when investigating dependence.  
Reward Center 
Perhaps the most commonly studied target of substance dependence is the 
mesocorticolimbic dopamine system, which mediates incentive motivation and approach 
behaviors evoked by natural rewards (e.g., sex, food, and social interactions; Feltenstein and See 
2008). The mesocorticolimbic system is constructed from two overlapping circuities called the 
mesolimbic and mesocortical dopaminergic systems that stem from dopaminergic neurons within 
the ventral tegmentum area (VTA) in the midbrain which sends projections to various forebrain 
structures (Chinta and Andersen 2005). The mesolimbic system is comprised of reciprocal 
projections from the VTA to the nucleus accumbens (NAc), amygdala, hippocampus, olfactory 
tubercle. While projections from the VTA to the prefrontal, cingulate and perirhinal cortices 
comprise the mesocortical system (Chinta and Andersen 2005), the dopaminergic projection 
from the VTA to the NAc is commonly referred to as the ‘final common pathway’ of dependence 
because inhibition of dopamine (DA) release or blockade of DA receptors in the NAc reduces or 
abolishes the reinforcing effects of drugs, drug-associated cues, and relapse-like behavior evoked 
by drug-associated cues (Feltenstein and See 2008). Increased DA in the NAc has been 
implicated in associative learning, incentive salience, reward prediction, and memory (Kelley 
and Berridge 2002). The NAc is also a point of convergence in the mesolimbic pathway; in 
addition to the dopaminergic projections from the VTA, the NAc receives glutamatergic 
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afferents from the prefrontal cortex (PFC) and hippocampus, which presumably also alter 
neuroplasticity in response to drugs of abuse (Lüscher and Malenka 2011). 
Indirect and Direct Pathways 
The NAc is located ventrally in the corpus striatum of the basal ganglia and is comprised 
of two parts: the core and shell (Dafney and Rosenfeld 2017). While DA is one of the main 
neurotransmitters released in the NAc, glutamate and GABA are also thought to help regulate 
goal-directed behaviors through integration of the limbic system (Dafney and Rosenfeld 2017). 
The neuronal structure of the ventral striatum is predominantly medium spiny neurons (MSNs) 
that synthesize the inhibitory neurotransmitter, GABA (Perreault et al. 2011). MSNs are 
subcategorized by their expression of dopamine D1 and D2-like G protein-coupled receptors and 
corresponding involvement in the indirect and direct pathways, although some overlapping exists 
(Lobo and Nestler 2011).  These two distinct pathways have been identified and used in 
understanding integration of reward and drug-seeking behaviors.  
The striatopallidal “indirect” pathway consists of MSNs that predominantly express 
dopamine D2-like receptors and project from the striatum to the external globus pallidus (GP) 
(Perreault et al. 2011). The second striatonigral “direct” pathway is known for dopamine D1-like 
receptor expression and projections to substantia nigra reticulata and internal segment of the GP 
(Perreault et al. 2011). The direct and indirect pathways are thought to combine to control 
thalamic output – with the indirect pathway serving as a ‘brake’ on the direct pathway (Perreault 
et al. 2011). DA is believed to have opposing effects on dopamine D1 and D2-like receptors 
within these two pathways (Gallo et al. 2018). Recent evidence has suggested that dopamine D1-
like receptors are low affinity (e.g., activated primarily by large increases in DA release) and 
activated in response to delivery of rewards and anticipation of rewards. In contrast, DA D2-like 
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receptors are low affinity (activated by small increases in DA tone) and appear to be associated 
with drug seeking mechanisms (Lobo and Nestler 2011). While addiction research of the NAc 
has allowed for insight into the mechanism of drug-associated reward and reinforcement, its 
efferents to thalamocortical circuits and their contributions to regulation of reward and approach 
behavior have been under-studied in the substance dependence literature (Smith et al. 2009).  
Innervation of Indirect Pathway onto the VP 
The ventral pallidum (VP) receives the primary GABA-ergic efferent from the NAc 
MSNs in the indirect pathway (Gallo et al. 2018). The VP was once considered part of the GP, 
but has more recently been identified as its own brain region (Smith et al. 2009). GABAergic 
neurons are the primary neuronal component of the VP and are associated with inputs of GABA 
and non-GABA transmission from the striatum (Root et al. 2015). Because of the location and 
reciprocating projections from various brain regions, it is hypothesized that the VP plays a 
crucial role in motor output for limbic motivation signals (Smith et al. 2009). The MSNs of the 
NAc project primarily to the VP which allows for incorporation of the direct and indirect 
pathways through D1 and D2-like receptor activity (Creed et al. 2016). A focus has been placed 
on the innervation of the MSNs expressing D2-like receptors and the VP. Activation of these D2-
like receptors are thought to reduce inhibitory transmission to the VP enhancing the motivation 
or willingness to work for a rewarding external stimuli (Gallo et al. 2018). Modifications to the 
indirect pathway could theoretically alter the incentive motivation for the reward. These types 
manipulations can be accomplished using a chemogenetic technique called DREADD. 
Neuronal Manipulation 
 Chemogenetics is becoming a more valued method when attempting to understand 
neuronal signal transduction. It can manipulate cells via alterations to proteins, G protein-
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coupled receptors, or ligand-gated ion channels (Roth 2016). Designer Receptors Exclusively 
Activated by Designer Drugs, or DREADD, is a form of a chemogenetic technique gaining 
acclamation because of its ability to distort neuronal transmission using a mutated G protein-
coupled receptor (GPCR) that only responds to a synthetically designed ligand. The design for 
the DREADD receptor evolved from the human seven-transmembrane domain muscarinic 
receptor. The developed receptor was mutated to specifically respond to clozapine-n-oxide 
(CNO) and metabolites but not to the endogenous ligand, acetylcholine (Zhu and Roth 2014). 
Recent evidence has shown that CNO metabolizes back into clozapine showing conflicting 
results of both CNO and clozapine activating DREADD receptors (Gomez et al. 2017) (Zhu and 
Roth 2014). Three DREADD signaling pathways have been produced and behave in different 
ways: hM3Dq induces neuronal transmission, hM4Di inhibits neuronal transmission, and rM3Ds 
which modulates neuronal activity (Zhu and Roth 2014). DREADD expression has shown to be 
high in injected brain regions because of the cell-type promoter associated with the DREADD 
genome and is tagged with a florescent protein. This also means that expression is not specific 
(Roth 2016). To increase specificity, a Cre-recombinase dependent DREADD was produced.  
 Cre-recombinase is an enzyme that recognizes specific regions within the DREADD 
genome. Expression of Cre-recombinase can be implicated through animal genetic modification 
and breeding or through viral administration discussed in detail below. DREADD expression 
became more selective with the production of a modified double-floxed open reading frame in an 
antisense configuration (Smith et al. 2016). Located on both sides of the reading frame are LoxP 
sites which are recognized by Cre-recombinase. Cre-recombinase cuts and flips the inverted gene 
transforming the reading frame into a sense configuration and allowing for DREADD expression 
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(Smith et al. 2016). This method increases selective targeting by restricting DREADD expression 
in neurons that do not already express Cre-recombinase.  
 As previously mentioned the genes responsible for Cre-recombinase and DREADD 
expression can be administered through viral applications. The common virus used is the Adeno 
Associated-Virus (AAV). AAV is not autonomously replicating unless the assistance from a 
helper virus occurs. While a virus may seem dangerous, to administer to animals or humans, 
researchers have constructed different AAVs to have little or no immune response (Mingozzi and 
High 2013). AAVs can infect cells through normal endocytosis or retrograde activity making 
them perfect for neuronal targeting. The Roth lab has combined the AAV and DREADD 
allowing for a molecular manipulation of neuronal transmission (Roth 2016).  
 In this study, Cre-dependent DREADD was used to manipulate and further understand 
the motivational pathway of the brain with nicotine. Currently addiction treatment consists of 
medication that mimics abusive drugs, behavioral counseling, treating withdrawal, and long-term 
follow up appointments (NIDA 2018). The brain is complex and is not fully understood. With 
that being said, this research combined with the studies previously mentioned could provide a 
more clear understanding about neuronal pathways associated with motivation and habitual drug 
use. Therefore providing new therapeutic opportunities and further insight into substance abuse 
disorder.  
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CHAPTER 2 
DREADD Targeting Projections from the Nucleus Accumbens to the Ventral Pallidum with 
Nicotine Self-Administration 
Introduction 
The nucleus accumbens (NAc) has been a major target in understanding the intricacy of 
drug dependence. Various research has shown the effects of commonly abused drugs on 
dopamine levels and receptors expressed on neurons within the NAc. With an increasing amount 
of data implicating the importance of the NAc to the reward of a drug, a new interest in incentive 
motivation has immerged. This has shifted the focus to the ventral pallidum (VP) and its role in 
drug incentive motor integration.  
 The NAc primarily consists of GABA transmitting medium spiny neurons (MSN) 
expressing D1-like and D2-like dopamine receptors. Cells that express D1-like receptors are part 
of the direct pathway – the receptors have lower affinity for dopamine (e.g., require more 
dopamine release before they are activated), therefore, stimulation of these receptors increases 
reward-based motivation and approach to incentive stimuli (Day and Carelli 2007). In contrast, 
D2-like receptors are high affinity (e.g., require less dopamine release to be activated) and are 
part of the ‘indirect pathway’ which regulates reward-based motivation and reduces approach to 
incentive stimuli (Hamada et al. 2004). Unlike D1 receptors which activate the direct pathway, 
D2-like receptors inhibit the indirect pathway. Inhibition would decrease the incentive 
motivational inhibitor and may have different effects on behavior. This would inhibit the indirect 
pathway and reduce inhibition on incentive behaviors, causing an increase in unfocused search 
behaviors. The indirect pathway includes projections from the NAc to the Ventral Pallidum 
(VP). Stimulation of NAc D2-like receptors decrease GABA release in the VP, which leads to a 
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‘release from inhibition’ on incentive motivation (Smith et al. 2009). All drugs of abuse activate 
the incentive motivational systems of the brain and either increase DA release in the NAc or 
mimic the effects of increased DA release in the NAc (Lüscher and Malenka 2011).  
The effects of nicotine on the direct and indirect pathway are currently unclear. For 
example, naïve rats exposed to nicotine injections showed approximately 100% increase in 
extracellular DA in the NAc (Rada et al. 2001), but this increase pales in comparison to other 
drugs of abuse such as cocaine, which can cause over 500% increases in extracellular DA 
(Andrews and Lucki 2001). Theoretically, nicotine induced DA release activates the indirect 
pathway implying that after brief activation by nicotine, a tobacco user’s incentive system might 
be released from inhibition – making them more sensitive to non-drug rewards because the 
indirect pathway has essentially been tuned-down. Such effects could make the act of smoking, 
the smoking-associated stimuli (flavors, smells, actions associated with smoking) and 
social/contextual cues (friends, alcohol drinking, bars, parties, etc.) more salient incentives and 
more likely to increase behavior in the future. Therefore, if the indirect pathway could be 
activated, a reduction in nicotine self-administration should be observed.  
To alter the indirect pathway, Designer Receptors Exclusively Activated by Designer 
Drugs, or DREADDs, was used to selectively target neurons projecting from the NAc to the VP 
pathways and control cellular function. DREADD is a single DNA strand containing the makeup 
for a designer G-coupled muscarinic receptor that, in this study, is dependent on Cre-
Recombinase (CRE) for expression (Kwon and Schaffer 2008). CRE, like DREADD, is not 
endogenous to neurons and must be implanted using an adeno-associated virus (AAV) that 
induces retrograde expression of CRE into the VP. All neurons with projections to the VP should 
be targeted and express CRE. The synapsin 1 promoter ensured that selectivity occurred of 
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targeted neurons and not glial cells (Madisen et al. 2015). After 2-3 weeks, CRE-dependent 
DREADD was injected into the NAc. By doing so, only neurons that project from the NAc to the 
VP should express the DREADD. Once the DREADD is expressed it can be activated by a low 
dose of clozapine, which was too low to bind to dopamine receptors (Gomez et al. 2017). The 
DREADD used changed the neuronal function by causing increased transmission. In this study, 
the DREADD was predicted to increase GABA release from the MSNs in the NAc to the VP, 
with the goal of increasing activity in the indirect pathway and reducing nicotine self-
administration. 
Hypotheses  
1. Activation of DREADD in the NAc will cause an increased GABA concentration in the 
VP. 
2. The administration of clozapine will not affect nicotine self-administration of control 
animals. 
3. Increased GABA release to the VP via activation of the indirect pathway will cause a 
reduction in nicotine self-administration. 
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Materials and Methods 
 
Subjects 
  Adult male Sprague Dawley rats (Charles River) were used for the experiment. Rats were 
individually housed and on a 12:12 hour light and dark cycle. All experiments took place during 
the dark cycle. Upon arrival, each rat had unrestricted access to food and water until weight 
exceeded 200 g. Food was then restricted to 15-20 g daily with unrestricted water for the 
remainder of the study.  
Apparatus 
Conditioning Chambers 
 Self-administration occurred in ten Med-Associates (Georgia, VT) operant chambers 
(ENV-008CT) measuring 30.5 × 25.4 × 30.5 (w × l × h). Each chamber individually housed a rat 
in a ventilated, sound and light attenuated enclosure. A receptacle containing a liquid dipper was 
located on the right side of the chamber. The dipper had a 0.1 ml cup attached to a motorized 
arm that delivered a sucrose reinforcer. The sucrose reinforcer was only used during training. 
Two retractable levers (ENV-112CM) were located on each side of the receptacle, 12 cm above 
the grid flooring. Pressing the active lever, left lever, earned a reinforcer. While pressing the 
inactive lever, right lever, resulted in no reinforcer earned. All lever presses were recorded. A 
stimulus light was located above each lever that would turn on when lever was pressed and 
retracted. During conditioning a house light located at the top of both sides of the chamber, 
approximately 28.5 cm above the floor, remained on until reinforcer was earned. House light 
would then turn off for a 30 second time out. Each operant conditioning chamber was equipped 
with a drug delivery system with a syringe pump (Med-Associates, model PHM100 – 10rpm) 
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that would deliver intravenous drug throughout all experiments. Recorded data collection from 
the operant chambers took place on a computer using MED-PC V software programming. 
Drugs and Solutions 
Intraperitoneal Solution 
Clozapine (Cayman Chemical) was dissolved into 1 ml of 1M HCl. NaOH was used to 
pH the solution to 7.0 (±2). The clozapine concentrations were tested between 0.03 - 0.75 mg/kg 
to find the most affective dose. Clozapine was administered into the peritoneal cavity (ip) 30 
minutes prior to the animal being placed into the operant chamber.  
Intravenous Solution 
Nicotine hydrogen tartrate salt (Stigma, St. Louis, MO) was diluted with 0.9% sterile 
saline to form a 30 g/kg concentration. NaOH was used to pH solution to 7.0 (±2). Nicotine 
was self-administered through the animal’s intrajugular catheter. The volume self-administered 
by the rat was weight dependent. For a control solution, 0.9% sterile saline was used.  
Surgery 
Surgery 1: Intravenous Catheter and Retro AAV Placement 
Intravenous Catheter. Each catheter was constructed using a blunt 22 gauge needle bent 
to form a 90o angle that was attached to a silastic tube (Dow Corning, Michigan) (0.51 ID x 0.94 
mm OD) 175 mm in length. To secure the tubing to the needle, a nylon washer (.09 x .25 x .062) 
(Fastenal, Minnesota) positioned on both sides of a round patch of polyester fabric (37.5 mm 
diameter) was placed at the base of the needle and fastened by medical device epoxy adhesive 
(LOCTITE EA M-21 HP, Henkel, North Carolina). Lastly, a silicone ball (3 mm diameter) was 
attached 40 mm from end of tubing using 100% RTV silicone (DAP, Maryland). All surgical 
equipment and catheters were sterilized by an autoclave treatment prior to surgery. Each rat was 
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placed under an inhaled anesthetic, Isoflurane USP (Henry Schein) and equipped with a chronic 
jugular vein catheter. The catheter exited between the two scapulae while the tubing was placed 
under the right front extremity. The tubing was then positioned into the right jugular (IV) and 
secured using two sutures. All incisions were closed using tissue staples. Ketoprofen (0.3mg/kg) 
was administered subcutaneously on day 0 and followed two days after surgery. Timentin 
(Ticarcillin and Clavulanate) diluted in heparinized saline was administered IV daily to prevent 
infection and platelet clot formation. The animals were allowed one week for recovery before 
nicotine self-administration began. Patency was checked consistently by injecting 0.2 mL 
PropoFlo (200mg/20mL) IV.  
Retro AAV. After catheter placement, each animal was placed in a stereotaxic apparatus 
and remained under Isoflurane. An estimated one inch incision was made exposing the rat’s 
skull. Bregma was measured and noted. The first bilateral intracranial injections targeted the 
rostro medial VP (1.6 AP, 1.8 ML, -7.9 DV) at a 10 degree angle. The second bilateral 
intracranial injection targeted the caudal lateral VP (-0.5 AP, 2.6 ML, -8.2 DV). The viral 
infusion rate was set to 0.1L/min with a total infusion of 0.5L for each injection. Incision was 
closed using tissue staples. Two weeks were given to allow for retrograde activity of the AAV 
and viral genomic expression of CRE-Recombinase.  
Surgery 2: AAV DREADD and Control Vector Placement  
DREADD or Control.  Each animal was anesthetized using Isoflurane and placed in a 
stereotaxic apparatus. Incision and closing were the same as previously demonstrated. The 
animals were divided into three groups: DREADD Nicotine, DREADD Saline, Control Nicotine. 
Both DREADD Nicotine and DREADD Saline groups were injected with AAV expressing CRE 
dependent DREADD into the NAc through bilateral intracranial injections (1.6 AP, 1.3 ML, -
 21 
7.3 DV). The Control Nicotine group received the control AAV into the NAc with the same 
coordinates stated above. For all intracranial injections into the NAc, the viral infusion rate was 
set to 0.1L/min with a total infusion of 1.0L for each injection.  
Procedures 
Experiment 1 
 Training. Prior to any surgery, rats were trained to lever press for a reinforcer of sucrose 
access through the receptacle. To begin, the left lever was inserted into the operant chamber for 
15 s followed by activation of the liquid dipper allowing 0.1 ml sucrose access for 0.5 s. If the 
lever was pressed during presentation, responses were recorded and the animal was given two 
sucrose reinforcers separated by 5 s. The animal needed to earn 60 reinforcers within a 1-h 
session to be considered successfully trained.  
Intravenous Nicotine or Saline Self-Administration. After IV catheter implantation and 
viral expression, rats were individually placed into the operant chambers and connected to the 
syringe pump containing nicotine 30 g/kg or 0.9% sterile saline. Once the session began, both 
retractable levers presented and operated on a fixed ratio (FR) for 1 h. Self-administration began 
on a FR2 and increased to ten over a period of sessions. An increase in the FR was dependent on 
data consistency. Once animals reached a FR10, Clozapine was administered chronically until 
data collection was complete.  
Microdialysis 
Experiment 2 
Microdialysis Surgery. Male Sprague Dawley rats (5n) that were placed under Isoflurane 
and stereotaxically implanted ipsilaterally with the Retro AAV containing CRE-Recombinase 
into the rostro medial VP (1.6 AP, 1.8 ML, -7.9 DV) at a 10 degree angle. Retro AAV was 
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allowed two weeks for expression. Rats were then ipsilaterally implanted with the AAV 
containing DREADD into the NAc (1.6 AP, 1.3 ML, -7.3 DV). Both viral infusions were 
0.1L/min with a total infusion of 1.0L for each injection. An 18 gauge, cut 11 mm below 
pedestal canula (PlasticsOne, Roanoke, VA.) was placed, on the same side as previous injections, 
into rostro medial VP (1.6 AP, 1.8 ML, -6.7 DV) at a 10 degree angle. Dummy stylets were 
placed into the cannula following surgery and reminded until the microdialysis collection 
session. Animals were allowed one week to recover. During recovery rats were placed into 
microdialysis chambers (Dr. Gerald Deehan PhD., East Tennessee State University) for a three 
day habituation. A loop style microdialysis probe was inserted 2 mm below cannula into the VP 
one day prior to microdialysis data collection.  
Microdialysis Collection Assembly 
 Gamma-Aminobutyric Acid, GABA, dialysate was collected by connecting the 
microdialysis probe directly to a microdialysis collection assembly. The assembly was 
constructed with two pieces of tubing. One side connected to a swivel that perfused aCSF 
towards the probe in the rat’s brain. This side was constructed 29 cm of PE20 tubing. The other 
side collected aCSF coming from the microdialysis probe and was constructed of 29 cm of PE10 
tubing with a ball 3 cm from the end. The plastic ball secured an amber vial and cap to the line.  
GABA Data Collection  
 One day following probe placement, the rats were placed into microdialysis chambers 
and connected to the collection assemblies. For the first 90 minutes one washout sample was 
collected. This helped eliminate any potential contaminates. After the first 90 minute sample, 
each sample was collected at 20 minute intervals. Baseline activity of GABA was collected over 
a period of 100 minutes. Immediately after the fifth sample was collected, 0.75 mg/kg Clozapine 
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was administered through intraperitoneal (IP) injections to each animal. Following the injection, 
five more samples were collected. Clozapine was injected IP at 1.50 mg/kg succeeding collecting 
ten more samples. This resulted in 400 minutes of total data collection. All samples were stored 
in a -80o. GABA dialysate was analyzed through electrochemical detection via graphite electrode 
using a EiCOM HTEC-510 HPLC machine (San Diego, CA). EiCOM AS-700 autosampler (San 
Diego, CA) controlled by the Envision software detected and quantified GABA dialysate 
samples using a one-sample t test.  
Microdialysis Solution 
 Artificial Cerebrospinal Fluid. Artificial cerebrospinal fluid (aCSF) microdialysis 
perfusion medium was composed of 145.0 NaCl, 2.7 KCl, 1.0 MgCl2, 2.5 CaCl2, and 2.0 
Na2HPO4. aCSF was filtered through a sterile filter (pore size, 0.2 μM), and prepared the day of 
microdialysis sessions. When necessary, the pH was adjusted to 7.4 with 0.1 N acetic acid. aCSF 
was perfused through 2 mm loop-style probes at a rate of 1.0 μl/min.  
 GABA Mobile Phase. GABA mobile phase used for GABA dialysate analysis via HPLC 
was composed of first dissolving 10.76 g NaH2PO4(2H2O), 3.95 g Na2HPO4(12H2O) in 800 mL 
of HPLC grade water with an end pH of 6.0. Next 50 mL of methanol was added with 130 mL 
acetonitrile, 5 mg EDTA(2Na). Solution was mixed until all particulate matter was dissolved. 
GABA Standard. GABA/Glutamate standards were constructed for HPLC calibration and 
controlled GABA and Glutamate detection. Standards were composed of -Aminobutyric acid 
and L-Glutamic acid (Sigma) and diluted to a concentration of 100 nM GABA and 10 M 
Glutamate using aCSF. 
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Tissue Collection and Storage 
Experiment 1 
Perfusion. Concluding behavioral testing, animals were sacrificed by an overdose of 
Isoflurane. During anesthesia, the animal was placed on its back and the thoracic cavity was 
opened to fully expose the heart. A 30 gauge needle with tubing connected to a pump was 
inserted into the left ventricle. A small laceration to the right atrium was placed to allow for 
blood to flow out of the circulatory system. The descending abdominal aorta is clamped to 
increase preservation of superior tissues. Once the needle had been placed, phosphate buffered 
saline (PBS) 1x was perfused throughout the tissue for 20 min followed by 4% 
paraformaldehyde. Once the blood had cleared from exposed tissues, the brain was then 
extracted. 
Tissue Fixation. The brains were placed in 4% paraformaldehyde in 4o for 24 h. The 
tissue was then transferred into PBS 1x and stored in 4o for a minimum of 24 h. To cryoprotect 
the tissue, brains were put in 30% sucrose and stored in 4o until tissue descended fully into 
solution. Next, each brain was rinsed in O.T.C compound (Fisherbrand) and placed in a new 
O.T.C for freezing. Brains were stored in a -80o.   
Experiment 2 
Directly after microdialysis, animals were sacrificed and tissue was preserved using the 
same perfusion procedure and tissue fixation as defined above. However prior to tissue 
extraction, Bromophenol blue (1%; 0.5μl) was perfused through the microdialysis probe to stain 
the VP to confirm correct probe placement. The tissue then underwent the same histology as 
experiment 1 described below.  
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Histology 
Tissue Slicing 
The fixed brain tissue was cryopreserved and coronally sliced at 20 m. The slices were 
immediately placed on colorfrost plus microscope slides (Fisherbrand) and stored at -20o.   
Tissue Staining  
Slides were kept in microscope slide box to reduce light exposure and allowed 30 min to 
dry at room temperature prior to staining. Tissue borders were defined using a hydrophobic pen 
and allowed to dry. The tissue was covered with a blocking solution containing PBS 1x, 2% 
bovine serum albumin, and 0.3% Triton x100 was added to the tissue for 1 hr at room 
temperature to increase tissue permeability. The blocking solution was then removed. Next the 
primary antibody, rabbit anti-mCherry antibody from Abcam, was diluted to 1:800 with the 
blocking solution defined above and added to fully cover sliced tissue. The primary antibody was 
incubated overnight at 4o Celsius.  
The following day, slides were washed (3 x 5 min) with a solution that contained PBS 1x 
with 3% Triton x100 (PBS-T). The secondary antibody, Alex 594 donkey anti-rabbit IgG from 
Jackson ImmunoResearch, diluted to 1:1000 in PBS-T was added to the tissue for a 2 h 
incubation at room temperature. Slides were then washed (2 x 15 min) with PBS-T. A third wash 
of PBS 1x for 15 min completed the staining process. The PBS 1x was removed and a 
fluorescence mounting medium, Fluro-Gel (Electron Microscopy Sciences) was added followed 
by a coverslip. After slides had dried overnight, a clear fingernail polish was applied to the 
corners to secure the coverslips. Slides were stored at 4o Celsius in the dark until imaging.  
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Fluorescence Imaging  
Tissue was viewed using an Olympus BX41 microscope (Olympus America, Inc.) at a 
wavelength of 594 nm (Dr. Donald Hoover, East Tennessee State University Biomedical 
Sciences). Imaging was used to confirm bilateral DREADD expression in the NAc.  
Statistical Analysis 
Experiment 1: Nicotine Self-Administration 
 To investigate the effect of Virus (Cre vs. DREADD) and Drug (nicotine vs. saline) on 
operant responding we conducted a 4-way mixed factors ANOVA with Virus and Drug as 
between groups factors and Lever (Active vs. Inactive) as within subjects factor. For acquisition 
Schedule (FR1, FR2, FR5, FR10) was a repeated measure. For clozapine challenge and saline 
recovery tests, Test (day of treatment) was the repeated measure. Because not all levels of Virus 
and Drug were represented in our design (e.g., no Cre-Saline group), some of the interactions 
(any including Drug and Virus) were not calculated. Drug and Virus conditions included were 
DREADD Nicotine (30 g/kg), Cre Nicotine, and DREADD Saline (0.9% sterile saline). Alpha 
criterion was set at p0.05, significant interactions were investigated with second-orders 
contrasts using Bonferroni’s correction for alpha inflation.  
Experiment 2: Microdialysis 
 The % baseline was calculated for each sample and compared to 100% using a one-
sample t-test. The analysis was able to detect the difference in % baseline extracellular GABA 
concentration after the first clozapine (0.75 mg/kg) and second clozapine (1.25 mg/kg) IP 
injections.  
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Results 
Experiment 1 
 Acquisition. Responding significantly increased during acquisition, but only on the active 
lever and only for rats that were self-administering nicotine. This was confirmed by a significant 
Drug x Lever x Schedule interaction, F(3,18)= 7.893, p= 0.001. Second-order contrasts 
confirmed that all groups showed greater active lever responding, relative to the inactive lever 
(ps≤0.012) on the FR1 schedule as seen in Figure 1. However, during the FR2, FR5, and FR10 
tests, this difference was observed in rats self-administering nicotine (ps<0.001) but not rats self-
administering saline (ps≥0.26). The difference between active and inactive levers in the Saline 
group under the FR1 schedule was most likely driven by prior food shaping (e.g., only the active 
lever was shaped). All animals were food shaped on an FR1 to promote lever pressing.  
 
Figure 1: Active Lever Presses for Acquisition. Nicotine enhanced acquisition of the active lever 
as FR increased. The DREADD Saline group decreased in active lever presses between FR1 and 
FR2 represented by the pound sign (#). Asterisks (*) represent the significant increase in active 
lever presses for nicotine as the FR increases.  
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 Treatment. An analysis of Virus x Levers x Tests between nicotine receiving groups 
revealed a decrease in DREADD Nicotine lever presses with administration of clozapine 
(0.75mg/kg) F(2,28) = 7.670, p = 0.002. The significance can be observed in Figure 2A on Test3 
of clozapine between Cre and DREADD Nicotine F(1,14) = 8.195, p = 0.013. However, further 
analysis of inactive lever presses also showed a significant decrease in DREADD Nicotine 
(ps0.027) represented in Figure 2B. Overall, clozapine decreased active and inactive lever 
responding in the DREADD Nicotine group. Lastly in reference to Figure 2A and 2B, clozapine 
injections were replaced with 0.9% sterile saline. While the DREADD Nicotine group appeared 
to gradually increase active lever responding, saline1 and saline2 showed a significant difference 
in both active F(1,20) = 8.718, p = 0.008; F(1,20) = 4.481 p = 0.047, and inactive levers 
(ps<0.001) when compared to Cre Nicotine.  
 
Figure 2A: Active Lever Presses with Treatment. DREADD Nicotine decreased active lever 
responding for nicotine in comparison to Cre Nicotine. Asterisks (*) represent the significant 
difference between both groups. Active lever presses are also represented when clozapine was 
replaced by saline.  
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Figure 2B: Inactive Lever Presses with Treatment. A significance, denoted by Asterisks (*), can 
be observed in inactive lever presses between Cre and DREADD Nicotine. Differences between 
inactive responding can also be seen in regards to saline replacement.  
 
Immunohistochemistry. The technique of immunohistochemistry (IHC) was performed to 
ensure expression of the DREADD receptor and expression in correct anatomical location. 
Perfused brain tissue was sliced at 20m and stained using a primary and secondary antibody. 
The secondary antibody fluoresced the marker mCherry that was seen using a Olympus BX41 
florescent microscope at the of wavelength 594 nm. The fluorescent mCherry indicated 
DREADD expression in the NAc shown in Figure 3A. Expression was also present throughout 
the entire neuron including cell body and projections represented in Figure 3B.  
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Figure 3A: DREADD Localization. The fluorescent mCherry marker for DREADD expression 
can be observed in the nucleus accumbens denoted NAc. Other anatomical landmarks are present 
– anterior commissure (ac) and the lateral ventricle (LV) seen on 4x magnification.  
 
 
 
Figure 3B: DREADD Expression. Expression throughout the neuron indicated by the mCherry 
marker. 
4x  
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Experiment 2 
 Microdialysis was performed to confirm that the administration of clozapine activated the 
DREADD receptor and caused an influx of GABA into the VP. Figure 4 shows that the first 
injection of clozapine (0.75 mg/kg) (M=143.948, SD=29.08422) significantly increased the 
concentration of GABA in the VP; t(4) = 3.379,  p = 0.028. Lastly, no significance was found 
with the second injection of clozapine (1.25 mg/kg), (p = 0.538).  
 
Figure 4: Amount of GABA (%Baseline). The effects of the two different injections of clozapine 
on % Baseline of GABA are shown. Asterisk (*) represent significance.  
 
 
 
 
 
 
 
 
 32 
Discussion 
 These experiments investigated the role of ventral striato-pallidal projections in nicotine 
self-administration in rats using a chemogenetic strategy to increase GABA inhibition in the 
indirect pathway of coritco-straito-thalamic circuits. To do so, a retrograde Cre-recombinase 
virus was injected into the ventral pallidum (VP), followed several weeks later by injection of a 
Cre-dependent DREADD receptor (hM3-DIO, cite) in the ventral striatum (nucleus accumbens, 
or NAc). This strategy should allow injections of the designer drug (clozapine) to cause burst 
firing of neurons projecting from the NAc to the VP, increasing GABA release, and activating 
the indirect pathway. After we established reliable intravenous nicotine self-administration, we 
found that clozapine administration increased GABA into the VP and caused a reduction in 
active lever presses for nicotine. However, we also observed a decrease in inactive lever 
responses, suggesting that the reduction of responding could have been a non-specific motor 
deficit. During a recovery phase (saline injections substituted for clozapine), the DREADD- 
Nicotine group took two sessions for nicotine self-administration to return to control levels. Most 
importantly, we found that the effects of clozapine were not based on off-target effects (e.g., 
dopamine D2 receptors) as a control group that did not receive DREADD receptors maintained 
high rates of responding for nicotine. We also confirmed that the DREADD receptor was 
expressed where we anticipated (NAc projection neurons) using IHC and that injection of 
clozapine increased extracellular GABA in the VP using HPLC. Several of the findings deserve 
further consideration, including the pattern of reduced nicotine self-administration and recovery 
after clozapine injections, the putative non-specific motor effects of clozapine injection, and the 
biochemical change in GABA observed in the microdialysis control experiment.  
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Nicotine Self-Administration  
 We hypothesized that by increasing GABA into the VP, the reinforcing effects of 
nicotine would decrease. Behavior consistent with the hypothesis was observed in active lever 
presses related to clozapine administration. Surprisingly, responding declined gradually 
suggesting that the activation of the DREADD receptor (e.g. increased GABA into the VP) 
decreased the reinforcing effects of nicotine through extinction. ‘Extinction’ refers to a pattern of 
operant responding that occurs when a reinforcer is removed – behavior gradually declines as the 
subject learns a new contingency (that the response no longer leads to a reinforcer). Similar 
experiments have increased GABA activity in the VP and revealed comparable results. 
Muscimol, a GABAA agonist, was injected directly into the VP resulting in a decrease in cocaine 
self-administration (Root et al. 2015). Also microinjections of neurotensin, a neuropeptide 
thought to increase GABA, into the VP correspondingly decrease cocaine self-administration 
(Torregrossa and Kalivas 2008). With the combined evidence of the current and previous studies, 
an increase in GABA into the VP decreased non-specific drug self-administration. However, 
further analysis of the current experiment depicted non-specific decrease in responding, as 
inactive lever responses also decreased during testing.  
 The VP is a critical component of the indirect pathway of cortico-striato-thalamic 
circuits. While any manipulation of striatal pathways could impact motor activity, the 
consequences of increasing GABA in the VP during nicotine self-administration on motor 
function has not been investigated. Our manipulation of increasing GABA by DREADD 
activation could have induced mild locomotor deficits as evidenced by decreased inactive lever 
responses. Inhibition of GABA receptors in the VP increases the initiation of activity in an open-
field test (Mogenson & Nielsen 1983). In addition, GABA injections in the VP reduce 
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hyperactivity caused by dopamine injections into the NAc (Mogenson & Nielsen 1983). Further 
experiments investigating locomotor activity and GABA concentration within the VP will be 
necessary to determine if the activation of the DREADD receptor decreased nicotine 
reinforcement or caused inhibition of motor activity. However, another study used neurotensin, a 
neuropeptide thought to increase GABA transmission by colocalizing with GABA release. 
Neurotensin was placed in the NAc and caused an increase in GABA release in the VP, 
extracellular GABA was measured with microdialysis. They found that the increase in GABA 
did not have any effect on locomotor activity (Torregrossa and Kalivas 2008). The GABA 
concentrations observed in our experiment were much lower when compared to the GABA 
influx caused by neurotensin. Yet, we found a decrease in inactive lever presses. This could be a 
result of the DREADD not being as specific as originally thought. The activation of D1 and D2-
like receptors may have had opposing effects.   
Another interesting finding was how the active and inactive levers differed in reduced 
responding with the administration of clozapine. Two days of clozapine injections were needed 
to see an observable reduction in active lever presses (for nicotine infusions) of the DREADD 
Nicotine group. Not until the third day was the group significantly different from Cre Nicotine in 
active lever presses. Additionally, two days of saline were necessary for the DREADD Nicotine 
to return to baseline nicotine responding. However, an immediate reduction in inactive lever 
presses was observed in response to the first day of clozapine injections of both DREADD 
Nicotine and Saline groups. Interestingly, the activity of inactive lever presses did not recover for 
either group during the two day saline recovery. Interpretation of inactive lever behavior can 
become complicated when considering that they may not be motivationally ‘neutral’. The 
inactive lever could obtain low motivational value because of its association with the active 
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lever. To further elaborate, with the DREADD Nicotine group, the inactive lever is physically 
comparable to the active lever that resulted in nicotine delivery. Similarly, the active lever for the 
DREADD Saline group historically resulted in sucrose delivery and is physically similar to the 
inactive lever. Because the possible connection between the two levers, inactive lever presses 
may not be an accurate measurement of spontaneous behavior when investigating motivation for 
a reward. Therefore, it is possible that increasing GABA in the VP also reduces motivation for a 
stimulus of low incentive value (inactive lever). Since this hypothesis is less parsimonious than 
simply effecting motor activity, it should be tested in an open-field locomotor task as well.  
 Expression of the DREADD was confirmed at the anatomical location of interest (NAc) 
with immunohistochemistry. Expression was observed in the both the core and shell of the NAc. 
This pattern of expression is consistent with anatomical tracing data showing that the NAc core 
and shell both send efferents to the VP. These subregions of the NAc both integrate in the direct 
and indirect pathways. MSNs expressing DA D1-like receptors are thought to be localized within 
the NAc core, while the MSNs expressing D2-like receptors are located in the shell (Root et al. 
2015). DA has opposing effects on D1 and D2-like receptors and has been studied extensively 
during drug self-administration. Other experiments have found that increasing D1 activity 
(exciting the direct pathway) or antagonizing D2-like receptors (inhibiting the indirect pathway) 
increases drug-seeking behaviors (Gallo et al. 2018). Nicotine is thought to alter the activity of 
both resulting in habitual use (Benowitz 2010). No research has shown the effects of increasing 
GABA using DREADD on D1 and D2-like receptor activity during nicotine self-administration. 
Indeed, one reason for the slow-recruiting effect of clozapine in DREADD Nicotine rats may be 
a lack of anatomical specificity. The DREADDs could have activated both direct and indirect 
pathway projections from the accumbens. According to Kupchik and Kalivas (2016), 
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differentiating the indirect and direct pathways based off D1 and D2-like receptors has been over 
simplified and needs further investigation into more distinguishing factors. The gradual decrease 
in nicotine self-administration observed in the presented data could have been a direct result of 
DREADD activating both pathways. With that being said, we would need to negate the possible 
counteractivity of nicotine and DREADD on the indirect and direct pathway.   
Future Directions 
 To confirm DREADD expression and microdialysis probe placement, the tissue from 
Experiment 2 will be sliced and stained. The implanted probe was injected with methylene blue 
prior to tissue collection. The tissue will be sliced and the NAc will be stained for DREADD 
expression while the methylene blue should be visible in the VP confirming correct probe 
placement.  
 Locomotor testing will be completed to investigate the activity of DREADD induced 
GABA release on the VP. The open field testing has been a reliable measure of locomotor 
activity (Metz et al. 2000) and will be applied to measure the locomotor activity of rats 
implanted with DREADD. Methods for viral implantation will be an exact replication of the 
current study. Further investigation of increasing GABA into the VP on motor activity will 
disclose if the observed decrease in inactive lever presses was overall decrease in motivation or 
induced locomotor deficit.  
Conclusion 
 The mesolimbic dopaminergic pathway is essential in substance abuse research. More 
and more evidence has revealed the importance of certain nuclei, within the mesolimbic 
pathway, in drug-associated behaviors. Investigating these projections has shown that the 
motivational role of the NAc to VP pathway may be an important regulatory afferent from the 
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mesolimbic system as part of the ‘indirect’ pathway. More recently this pathway has been 
targeted by various manipulations resulting in the further understanding of its effects on drug 
self-administration. This is the first time the NAc to VP pathway has been investigated for its 
role in the reinforcing effects of nicotine with chemogenetic techniques. In conclusion, future 
data combined with current will provide a clearer representation of the effects GABA in the VP 
during drug-seeking behaviors.  
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